{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T22:39:07Z","timestamp":1771713547922,"version":"3.50.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1038\/nrc1359","type":"journal-article","created":{"date-parts":[[2004,4,30]],"date-time":"2004-04-30T14:39:38Z","timestamp":1083335978000},"page":"401-411","source":"Crossref","is-referenced-by-count":215,"title":["The promise of cancer vaccines"],"prefix":"10.1038","volume":"4","author":[{"given":"Eli","family":"Gilboa","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BFnrc1359_CR1","first-page":"713","volume":"8","author":"HC Nauts","year":"1989","unstructured":"Nauts, H. C. Bacteria and cancer: antagonisms and benefits. Cancer Surv. 8, 713\u2013723 (1989).","journal-title":"Cancer Surv."},{"key":"BFnrc1359_CR2","first-page":"769","volume":"18","author":"RT Prehn","year":"1957","unstructured":"Prehn, R. T. & Main, J. M. Immunity to methylcholantrene-induced sarcomas. J. Natl Cancer Inst. 18, 769\u2013778 (1957).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1359_CR3","first-page":"1561","volume":"20","author":"G Klein","year":"1960","unstructured":"Klein, G., Sogren, H. O., Klein, H. & Hellstrom, K. E. Demonstration of resistance against methylcholantrene-induced sarcomas in primary autochtonous host. Cancer Res. 20, 1561\u20131572 (1960).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR4","volume-title":"Discussions of cellular and humoral aspects of the hypersensitive states","author":"L Thomas","year":"1959","unstructured":"Thomas, L. Discussions of cellular and humoral aspects of the hypersensitive states (Hoeber\u2013Harper, New York, 1959)."},{"key":"BFnrc1359_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","volume":"13","author":"FM Burnet","year":"1970","unstructured":"Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1\u201327 (1970).","journal-title":"Prog. Exp. Tumor Res."},{"key":"BFnrc1359_CR6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0889-8561(22)00329-0","volume":"11","author":"P Livingston","year":"1991","unstructured":"Livingston, P. Active specific immunotherapy in the treatment of patients with cancer. Immunol. Allergy Clin. North Am. 11, 410\u2013430 (1991).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"BFnrc1359_CR7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bjc.1976.37","volume":"33","author":"HB Hewitt","year":"1976","unstructured":"Hewitt, H. B., Blake, E. R. & Walder, A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33, 241\u2013259 (1976).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1359_CR8","first-page":"353","volume":"62","author":"O Stutman","year":"1979","unstructured":"Stutman, O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl Cancer Inst. 62, 353\u2013358 (1979).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1359_CR9","first-page":"99","volume":"82","author":"J Rygaard","year":"1974","unstructured":"Rygaard, J. & Povlsen, C. O. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol. Microbiol. Scand. Microbiol. Immunol. [B] 82, 99\u2013106 (1974).","journal-title":"Acta Pathol. Microbiol. Scand. Microbiol. Immunol. [B]"},{"key":"BFnrc1359_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q","volume":"28","author":"RA Gatti","year":"1971","unstructured":"Gatti, R. A. & Good, R. A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28, 89\u201398 (1971).","journal-title":"Cancer"},{"key":"BFnrc1359_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.me.39.020188.000431","volume":"39","author":"I Penn","year":"1988","unstructured":"Penn, I. Tumors of the immunocompromised patient. Annu. Rev. Med. 39, 63\u201373 (1988).","journal-title":"Annu. Rev. Med."},{"key":"BFnrc1359_CR12","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1073\/pnas.79.15.4718","volume":"79","author":"A Van Pel","year":"1982","unstructured":"Van Pel, A. & Boon, T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718\u20134722 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991\u2013998 (2002).","journal-title":"Nature Immunol."},{"key":"BFnrc1359_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/86297","volume":"2","author":"MJ Smyth","year":"2001","unstructured":"Smyth, M. J., Godfrey, D. I. & Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunol. 2, 293\u2013299 (2001).","journal-title":"Nature Immunol."},{"key":"BFnrc1359_CR15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","volume":"21","author":"D Pardoll","year":"2003","unstructured":"Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807\u2013839 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107\u20131111 (2001).","journal-title":"Nature"},{"key":"BFnrc1359_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1615\/CritRevOncog.v8.i2-3.10","volume":"8","author":"G Pawelec","year":"1997","unstructured":"Pawelec, G., Zeuthen, J. & Kiessling, R. Escape from host-antitumor immunity. Crit. Rev. Oncog. 8, 111\u2013141 (1997).","journal-title":"Crit. Rev. Oncog."},{"key":"BFnrc1359_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181\u2013273 (2000).","journal-title":"Adv. Immunol."},{"key":"BFnrc1359_CR19","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1054\/bjoc.2000.1217","volume":"82","author":"AG Dalgleish","year":"2000","unstructured":"Dalgleish, A. G. Cancer vaccines. Br. J. Cancer 82, 1619\u20131624 (2000).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1359_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0167-5699(98)01299-7","volume":"19","author":"D Mason","year":"1998","unstructured":"Mason, D. A very high level of crossreactivity is an essential feature of the T- cell receptor. Immunol. Today 19, 395\u2013404 (1998).","journal-title":"Immunol. Today"},{"key":"BFnrc1359_CR21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.184.4.1259","volume":"184","author":"GJ Kersh","year":"1996","unstructured":"Kersh, G. J. & Allen, P. M. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 184, 1259\u20131268 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695\u2013705 (1995).","journal-title":"Cell"},{"key":"BFnrc1359_CR23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.2321019","volume":"247","author":"H Schild","year":"1990","unstructured":"Schild, H., Rotzschke, O., Kalbacher, H. & Rammensee, H. G. Limit of T cell tolerance to self proteins by peptide presentation. Science 247, 1587\u20131589 (1990).","journal-title":"Science"},{"key":"BFnrc1359_CR24","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.4049\/jimmunol.164.10.5508","volume":"164","author":"A Heiser","year":"2000","unstructured":"Heiser, A. et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164, 5508\u20135514 (2000).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1074-7613(00)00080-7","volume":"13","author":"C Bouneaud","year":"2000","unstructured":"Bouneaud, C., Kourilsky, P. & Bousso, P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829\u2013840 (2000).","journal-title":"Immunity"},{"key":"BFnrc1359_CR26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.160.2.643","volume":"160","author":"DJ Morgan","year":"1998","unstructured":"Morgan, D. J. et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643\u2013651 (1998).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1458::AID-IMMU1458>3.0.CO;2-2","volume":"30","author":"KE de Visser","year":"2000","unstructured":"de Visser, K. E. et al. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur. J. Immunol. 30, 1458\u20131468 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnrc1359_CR28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991\u20131045 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0167-5699(92)90198-G","volume":"13","author":"CA Janeway Jr.","year":"1992","unstructured":"Janeway, C. A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11\u201316 (1992).","journal-title":"Immunol. Today"},{"key":"BFnrc1359_CR30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252 (1998).","journal-title":"Nature"},{"key":"BFnrc1359_CR31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","volume":"21","author":"RM Steinman","year":"2003","unstructured":"Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685\u2013711 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1074-7613(01)00136-4","volume":"14","author":"C Reis e Sousa","year":"2001","unstructured":"Reis e Sousa, C. Dendritic cells as sensors of infection. Immunity 14, 495\u2013498 (2001).","journal-title":"Immunity"},{"key":"BFnrc1359_CR33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1146\/annurev.immunol.17.1.829","volume":"17","author":"E Sebzda","year":"1999","unstructured":"Sebzda, E. et al. Selection of the T cell repertoire. Annu. Rev. Immunol. 17, 829\u2013874 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1126\/science.280.5361.243","volume":"280","author":"L Van Parijs","year":"1998","unstructured":"Van Parijs, L. & Abbas, A. K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280, 243\u2013248 (1998).","journal-title":"Science"},{"key":"BFnrc1359_CR35","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1084\/jem.187.10.1555","volume":"187","author":"AJ Adler","year":"1998","unstructured":"Adler, A. J. et al. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187, 1555\u20131564 (1998).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.186.2.239","volume":"186","author":"C Kurts","year":"1997","unstructured":"Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. & Heath, W. R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J. Exp. Med. 186, 239\u2013245 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1073\/pnas.231606698","volume":"99","author":"RM Steinman","year":"2002","unstructured":"Steinman, R. M. & Nussenzweig, M. C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl Acad. Sci. USA 99, 351\u2013358 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.18.1.423","volume":"18","author":"EM Shevach","year":"2000","unstructured":"Shevach, E. M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423\u2013449 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-065X.2001.1820105.x","volume":"182","author":"MG Roncarolo","year":"2001","unstructured":"Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S. & Levings, M. K. Type 1 T regulatory cells. Immunol. Rev. 182, 68\u201379 (2001).","journal-title":"Immunol. Rev."},{"key":"BFnrc1359_CR40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0952-7915(01)00273-4","volume":"13","author":"S Read","year":"2001","unstructured":"Read, S. & Powrie, F. CD4+ regulatory T cells. Curr. Opin. Immunol. 13, 644\u2013649 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc1359_CR41","first-page":"677","volume":"25","author":"V Schirrmacher","year":"1998","unstructured":"Schirrmacher, V. et al. Immunization with virus-modified tumor cells. Semin. Oncol. 25, 677\u2013696 (1998).","journal-title":"Semin. Oncol."},{"key":"BFnrc1359_CR42","first-page":"611","volume":"25","author":"AD Chan","year":"1998","unstructured":"Chan, A. D. & Morton, D. L. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin. Oncol. 25, 611\u2013622 (1998).","journal-title":"Semin. Oncol."},{"key":"BFnrc1359_CR43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri820","volume":"2","author":"RM Welsh","year":"2002","unstructured":"Welsh, R. M. & Selin, L. K. No one is naive: the significance of heterologous T-cell immunity. Nature Rev. Immunol. 2, 417\u2013426 (2002).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc1359_CR44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1600-065X.2003.00082.x","volume":"196","author":"AB Adams","year":"2003","unstructured":"Adams, A. B., Pearson, T. C. & Larsen, C. P. Heterologous immunity: an overlooked barrier to tolerance. Immunol. Rev. 196, 147\u2013160 (2003).","journal-title":"Immunol. Rev."},{"key":"BFnrc1359_CR45","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1073\/pnas.93.9.4102","volume":"93","author":"MA Alexander-Miller","year":"1996","unstructured":"Alexander-Miller, M. A., Leggatt, G. R. & Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102\u20134107 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.162.2.989","volume":"162","author":"HJ Zeh 3rd","year":"1999","unstructured":"Zeh, H. J. 3rd, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. & Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989\u2013994 (1999).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4049\/jimmunol.168.2.651","volume":"168","author":"TA Cordaro","year":"2002","unstructured":"Cordaro, T. A., de Visser, K. E., Tirion, F. H., Schumacher, T. N. & Kruisbeek, A. M. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 168, 651\u2013660 (2002).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1074-7613(00)80101-6","volume":"11","author":"E Gilboa","year":"1999","unstructured":"Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263\u2013270 (1999).","journal-title":"Immunity"},{"key":"BFnrc1359_CR49","first-page":"3230","volume":"61","author":"LA Loeb","year":"2001","unstructured":"Loeb, L. A. A mutator phenotype in cancer. Cancer Res. 61, 3230\u20133239 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","volume":"396","author":"C Lengauer","year":"1998","unstructured":"Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643\u2013649 (1998).","journal-title":"Nature"},{"key":"BFnrc1359_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.183.1.87","volume":"183","author":"L Zitvogel","year":"1996","unstructured":"Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87\u201397 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR52","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","volume":"95","author":"RC Fields","year":"1998","unstructured":"Fields, R. C., Shimizu, K. & Mule, J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95, 9482\u20139487 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR53","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539\u20133543 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","volume":"184","author":"D Boczkowski","year":"1996","unstructured":"Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465\u2013472 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR55","first-page":"1028","volume":"60","author":"D Boczkowski","year":"2000","unstructured":"Boczkowski, D., Nair, S. K., Nam, J. H., Lyerly, H. K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028\u20131034 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.gt.3301901","volume":"10","author":"F Grunebach","year":"2003","unstructured":"Grunebach, F., Muller, M. R., Nencioni, A. & Brossart, P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. 10, 367\u2013374 (2003).","journal-title":"Gene Ther."},{"key":"BFnrc1359_CR57","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/79519","volume":"6","author":"SK Nair","year":"2000","unstructured":"Nair, S. K. et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med. 6, 1011\u20131017 (2000).","journal-title":"Nature Med."},{"key":"BFnrc1359_CR58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1074-7613(00)80066-7","volume":"10","author":"RH Vonderheide","year":"1999","unstructured":"Vonderheide, R. H., Hahn, W. C., Schultze, J. L. & Nadler, L. M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673\u2013679 (1999).","journal-title":"Immunity"},{"key":"BFnrc1359_CR59","first-page":"4845","volume":"60","author":"M Schmitz","year":"2000","unstructured":"Schmitz, M. et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60, 4845\u20134849 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR60","first-page":"5964","volume":"61","author":"MH Andersen","year":"2001","unstructured":"Andersen, M. H. et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61, 5964\u20135968 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR61","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.4049\/jimmunol.170.11.5391","volume":"170","author":"M Zeis","year":"2003","unstructured":"Zeis, M. et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-rna-transfected dendritic cells. J. Immunol. 170, 5391\u20135397 (2003).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR62","first-page":"207","volume":"5","author":"AL Barsoum","year":"2000","unstructured":"Barsoum, A. L., Rohrer, J. W. & Coggin, J. H. 37kDa oncofetal antigen is an autoimmunogenic homologoue of the 37kDa laminin receptor precursor. Cell. Mol. Biol. Lett. 5, 207\u2013230 (2000).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"BFnrc1359_CR63","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.4049\/jimmunol.167.11.6644","volume":"167","author":"A Biragyn","year":"2001","unstructured":"Biragyn, A. et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167, 6644\u20136653 (2001).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR64","first-page":"3704","volume":"61","author":"Z You","year":"2001","unstructured":"You, Z., Huang, X., Hester, J., Toh, H. C. & Chen, S. Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61, 3704\u20133711 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR65","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","volume":"194","author":"D Hawiger","year":"2001","unstructured":"Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769\u2013779 (2001).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR66","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","volume":"196","author":"L Bonifaz","year":"2002","unstructured":"Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor dec-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T Cell Tolerance. J. Exp. Med. 196, 1627\u20131638 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR67","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.4049\/jimmunol.169.9.5322","volume":"169","author":"TD de Gruijl","year":"2002","unstructured":"de Gruijl, T. D. et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169, 5322\u20135331 (2002).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR68","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","volume":"166","author":"B Almand","year":"2001","unstructured":"Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678\u2013689 (2001).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR69","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150\u20134166 (1998).","journal-title":"Blood"},{"key":"BFnrc1359_CR70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.immunol.18.1.245","volume":"18","author":"L Fong","year":"2000","unstructured":"Fong, L. & Engleman, E. G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245\u2013273 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1615\/CritRevImmunol.v21.i1-3.90","volume":"21","author":"M Gunzer","year":"2001","unstructured":"Gunzer, M. & Grabbe, S. Dendritic cells in cancer immunotherapy. Crit. Rev. Immunol. 21, 133\u2013145 (2001).","journal-title":"Crit. Rev. Immunol."},{"key":"BFnrc1359_CR72","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0301-472X(01)00730-5","volume":"29","author":"P Brossart","year":"2001","unstructured":"Brossart, P., Wirths, S., Brugger, W. & Kanz, L. Dendritic cells in cancer vaccines. Exp. Hematol. 29, 1247\u20131255 (2001).","journal-title":"Exp. Hematol."},{"key":"BFnrc1359_CR73","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0952-7915(98)80228-8","volume":"10","author":"DM Pardoll","year":"1998","unstructured":"Pardoll, D. M. & Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588\u2013594 (1998).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc1359_CR74","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.189.5.753","volume":"189","author":"RE Toes","year":"1999","unstructured":"Toes, R. E., Ossendorp, F., Offringa, R. & Melief, C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753\u2013756 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1471-4906(01)01896-8","volume":"22","author":"RF Wang","year":"2001","unstructured":"Wang, R. F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22, 269\u2013276 (2001).","journal-title":"Trends Immunol."},{"key":"BFnrc1359_CR76","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","volume":"421","author":"EM Janssen","year":"2003","unstructured":"Janssen, E. M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852\u2013856 (2003).","journal-title":"Nature"},{"key":"BFnrc1359_CR77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1083317","volume":"300","author":"JC Sun","year":"2003","unstructured":"Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339\u2013342 (2003).","journal-title":"Science"},{"key":"BFnrc1359_CR78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337\u2013339 (2003).","journal-title":"Science"},{"key":"BFnrc1359_CR79","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1084\/jem.188.12.2199","volume":"188","author":"SA Kalams","year":"1998","unstructured":"Kalams, S. A. & Walker, B. D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199\u20132204 (1998).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR80","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0952-7915(98)80119-2","volume":"10","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J., Murali-Krishna, K., Blattman, J. N. & Ahmed, R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10, 444\u2013449 (1998).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc1359_CR81","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","volume":"95","author":"DH Kaplan","year":"1998","unstructured":"Kaplan, D. H. et al. Demonstration of an interferon \u03b3-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556\u20137561 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1074-7613(00)80218-6","volume":"12","author":"Z Qin","year":"2000","unstructured":"Qin, Z. & Blankenstein, T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN \u03b3 receptor expression by nonhematopoietic cells. Immunity 12, 677\u2013686 (2000).","journal-title":"Immunity"},{"key":"BFnrc1359_CR83","doi-asserted-by":"crossref","first-page":"8633","DOI":"10.1073\/pnas.96.15.8633","volume":"96","author":"D Mumberg","year":"1999","unstructured":"Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-\u03b3. Proc. Natl Acad. Sci. USA 96, 8633\u20138638 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR84","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1084\/jem.161.5.1122","volume":"161","author":"PD Greenberg","year":"1985","unstructured":"Greenberg, P. D., Kern, D. E. & Cheever, M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161, 1122\u20131134 (1985).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR85","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.174.6.1291","volume":"174","author":"H Hock","year":"1991","unstructured":"Hock, H., Dorsch, M., Diamantstein, T. & Blankenstein, T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174, 1291\u20131298 (1991).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1084\/jem.179.4.1215","volume":"179","author":"HI Levitsky","year":"1994","unstructured":"Levitsky, H. I., Lazenby, A., Hayashi, R. J. & Pardoll, D. M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215\u20131224 (1994).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR87","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357\u20132368 (1998).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-065X.1998.tb01245.x","volume":"165","author":"P Marrack","year":"1998","unstructured":"Marrack, P. et al. T-cell survival. Immunol. Rev. 165, 279\u2013285 (1998).","journal-title":"Immunol. Rev."},{"key":"BFnrc1359_CR89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-2478(98)00119-9","volume":"65","author":"J Sprent","year":"1999","unstructured":"Sprent, J., Zhang, X., Sun, S. & Tough, D. T-cell turnover in vivo and the role of cytokines. Immunol. Lett. 65, 21\u201325 (1999).","journal-title":"Immunol. Lett."},{"key":"BFnrc1359_CR90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","volume":"1","author":"J Hendriks","year":"2000","unstructured":"Hendriks, J. et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nature Immunol. 1, 433\u2013440 (2000).","journal-title":"Nature Immunol."},{"key":"BFnrc1359_CR91","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/smim.1998.0146","volume":"10","author":"AD Weinberg","year":"1998","unstructured":"Weinberg, A. D., Vella, A. T. & Croft, M. OX-40: life beyond the effector T cell stage. Semin. Immunol. 10, 471\u2013480 (1998).","journal-title":"Semin. Immunol."},{"key":"BFnrc1359_CR92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1471-4906(02)02263-9","volume":"23","author":"B Kwon","year":"2002","unstructured":"Kwon, B., Lee, H. W. & Kwon, B. S. New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells. Trends Immunol. 23, 378\u2013380 (2002).","journal-title":"Trends Immunol."},{"key":"BFnrc1359_CR93","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/418252a","volume":"418","author":"BA Sullenger","year":"2002","unstructured":"Sullenger, B. A. & Gilboa, E. Emerging clinical applications of RNA. Nature 418, 252\u2013258 (2002).","journal-title":"Nature"},{"key":"BFnrc1359_CR94","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","volume":"1","author":"ML Alegre","year":"2001","unstructured":"Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. T-cell regulation by CD28 and CTLA-4. Nature Rev. Immunol. 1, 220\u2013228 (2001).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc1359_CR95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","volume":"19","author":"B Salomon","year":"2001","unstructured":"Salomon, B. & Bluestone, J. A. Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225\u2013252 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR96","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565\u2013594 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","volume":"20","author":"BM Carreno","year":"2002","unstructured":"Carreno, B. M. & Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29\u201353 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR98","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"JG Egen","year":"2002","unstructured":"Egen, J. G., Kuhns, M. S. & Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3, 611\u2013618 (2002).","journal-title":"Nature Immunol."},{"key":"BFnrc1359_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002620050498","volume":"47","author":"KK Bass","year":"1998","unstructured":"Bass, K. K. & Mastrangelo, M. J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother. 47, 1\u201312 (1998).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1359_CR100","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211\u20135218 (1999).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR101","first-page":"3128","volume":"59","author":"S Onizuka","year":"1999","unstructured":"Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor \u03b1) monoclonal antibody. Cancer Res. 59, 3128\u20133133 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR102","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823\u2013832 (2001).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR103","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"L Gorelik","year":"2001","unstructured":"Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-\u03b2 signaling in T cells. Nature Med. 7, 1118\u20131122 (2001).","journal-title":"Nature Med."},{"key":"BFnrc1359_CR104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793\u2013800 (2002).","journal-title":"Nature Med."},{"key":"BFnrc1359_CR105","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-002-0280-8","volume":"51","author":"S Kusmartsev","year":"2002","unstructured":"Kusmartsev, S. & Gabrilovich, D. I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51, 293\u2013298 (2002).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1359_CR107","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","volume":"24","author":"V Bronte","year":"2003","unstructured":"Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M. & Zanovello, P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24, 302\u2013306 (2003).","journal-title":"Trends Immunol."},{"key":"BFnrc1359_CR108","first-page":"4441","volume":"63","author":"S Kusmartsev","year":"2003","unstructured":"Kusmartsev, S. et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441\u20134449 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"A van Elsas","year":"1999","unstructured":"van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355\u2013366 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR110","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372\u20138377 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR111","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712\u20134717 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR112","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1084\/jem.192.4.F9","volume":"192","author":"CD Surh","year":"2000","unstructured":"Surh, C. D. & Sprent, J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J. Exp. Med. 192, F9\u2013F14 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR113","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1073\/pnas.98.4.1728","volume":"98","author":"Q Ge","year":"2001","unstructured":"Ge, Q., Rao, V. P., Cho, B. K., Eisen, H. N. & Chen, J. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide\/MHC epitopes and strength of their interaction with T cell receptors. Proc. Natl Acad. Sci. USA 98, 1728\u20131733 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1084\/jem.20021812","volume":"197","author":"G Kassiotis","year":"2003","unstructured":"Kassiotis, G., Zamoyska, R. & Stockinger, B. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J. Exp. Med. 197, 1007\u20131016 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR115","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V95.10.3011","volume":"95","author":"I Borrello","year":"2000","unstructured":"Borrello, I. et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011\u20133019 (2000).","journal-title":"Blood"},{"key":"BFnrc1359_CR116","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI0215175","volume":"110","author":"W Dummer","year":"2002","unstructured":"Dummer, W. et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185\u2013192 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrc1359_CR117","first-page":"3914","volume":"62","author":"HM Hu","year":"2002","unstructured":"Hu, H. M., Poehlein, C. H., Urba, W. J. & Fox, B. A. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62, 3914\u20133919 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR118","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.022634999","volume":"99","author":"W Asavaroengchai","year":"2002","unstructured":"Asavaroengchai, W., Kotera, Y. & Mule, J. J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl Acad. Sci. USA 99, 931\u2013936 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR119","doi-asserted-by":"crossref","first-page":"14809","DOI":"10.1073\/pnas.93.25.14809","volume":"93","author":"C Naftzger","year":"1996","unstructured":"Naftzger, C. et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl Acad. Sci. USA 93, 14809\u201314814 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR120","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1073\/pnas.96.6.2982","volume":"96","author":"WW Overwijk","year":"1999","unstructured":"Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982\u20132987 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR121","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.159.7.3113","volume":"159","author":"L Fong","year":"1997","unstructured":"Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G. & Laus, R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159, 3113\u20133117 (1997).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR122","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4049\/jimmunol.163.1.32","volume":"163","author":"BN Dittel","year":"1999","unstructured":"Dittel, B. N., Visintin, I., Merchant, R. M. & Janeway, C. A. Jr. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol. 163, 32\u201339 (1999).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR123","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1084\/jem.191.5.795","volume":"191","author":"B Ludewig","year":"2000","unstructured":"Ludewig, B. et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795\u2013804 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR124","first-page":"253","volume":"60","author":"V Bronte","year":"2000","unstructured":"Bronte, V. et al. Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 60, 253\u2013258 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR125","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/JVI.71.5.3998-4004.1997","volume":"71","author":"I Melero","year":"1997","unstructured":"Melero, I. et al. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71, 3998\u20134004 (1997).","journal-title":"J. Virol."},{"key":"BFnrc1359_CR126","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1084\/jem.177.6.1681","volume":"177","author":"J Hu","year":"1993","unstructured":"Hu, J. et al. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177, 1681\u20131690 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR127","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1172\/JCI118958","volume":"98","author":"MJ Maeurer","year":"1996","unstructured":"Maeurer, M. J. et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1\/Melan-A antigen. J. Clin. Invest. 98, 1633\u20131641 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrc1359_CR128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0","volume":"71","author":"E Jager","year":"1997","unstructured":"Jager, E. et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142\u2013147 (1997).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1359_CR129","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168\u201316173 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","volume":"17","author":"JW Yewdell","year":"1999","unstructured":"Yewdell, J. W. & Bennink, J. R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51\u201388 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc1359_CR131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrc1255","volume":"4","author":"ML Albert","year":"2004","unstructured":"Albert, M. L. & Darnell, R. B. Paraneoplastic neurological degenerations: keys to tumour immunity. Nature Rev. Cancer 4, 36\u201344 (2004).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1359_CR132","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1073\/pnas.93.10.4781","volume":"93","author":"J Roth","year":"1996","unstructured":"Roth, J. et al. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl Acad. Sci. USA 93, 4781\u20134786 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1359_CR133","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.186.5.645","volume":"186","author":"DE Speiser","year":"1997","unstructured":"Speiser, D. E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645\u2013653 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR134","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0952-7915(00)00197-7","volume":"13","author":"BJ Van den Eynde","year":"2001","unstructured":"Van den Eynde, B. J. & Morel, S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr. Opin. Immunol. 13, 147\u2013153 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc1359_CR135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach, A., Jensen, E. R., Jamieson, A. M. & Raulet, D. H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413, 165\u2013171 (2001).","journal-title":"Nature"},{"key":"BFnrc1359_CR136","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/85321","volume":"2","author":"V Groh","year":"2001","unstructured":"Groh, V. et al. Costimulation of CD8\u03b1\u03b2 T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nature Immunol. 2, 255\u2013260 (2001).","journal-title":"Nature Immunol."},{"key":"BFnrc1359_CR137","first-page":"77","volume":"3","author":"HF Dvorak","year":"1991","unstructured":"Dvorak, H. F., Nagy, J. A. & Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77\u201385 (1991).","journal-title":"Cancer Cells"},{"key":"BFnrc1359_CR138","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.2001.19.6.1848","volume":"19","author":"RM Simon","year":"2001","unstructured":"Simon, R. M. et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19, 1848\u20131854 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1359_CR139","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.4049\/jimmunol.171.11.6275","volume":"171","author":"S Nair","year":"2003","unstructured":"Nair, S. et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171, 6275\u20136282 (2003).","journal-title":"J. Immunol."},{"key":"BFnrc1359_CR140","first-page":"7483","volume":"63","author":"S Santulli-Marotto","year":"2003","unstructured":"Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B. & Gilboa, E. Multivalent RNA aptamers that inhibit ctla-4 and enhance tumor immunity. Cancer Res. 63, 7483\u20137489 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1359_CR141","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2002-12-3738","volume":"102","author":"S Nair","year":"2003","unstructured":"Nair, S. et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102, 964\u2013971 (2003).","journal-title":"Blood"},{"key":"BFnrc1359_CR142","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2003-06-1867","volume":"102","author":"Y Zhao","year":"2003","unstructured":"Zhao, Y., Boczkowski, D., Nair, S. K. & Gilboa, E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 102, 4137\u20134142 (2003).","journal-title":"Blood"},{"key":"BFnrc1359_CR143","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","volume":"411","author":"LA Liotta","year":"2001","unstructured":"Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375\u2013379 (2001).","journal-title":"Nature"},{"key":"BFnrc1359_CR144","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/80506","volume":"6","author":"YQ Wei","year":"2000","unstructured":"Wei, Y. Q. et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nature Med. 6, 1160\u20131166 (2000).","journal-title":"Nature Med."},{"key":"BFnrc1359_CR145","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.20020072","volume":"195","author":"Y Li","year":"2002","unstructured":"Li, Y. et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195, 1575\u20131584 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnrc1359_CR146","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm1202-794","volume":"8","author":"AG Niethammer","year":"2002","unstructured":"Niethammer, A. G. et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med. 8, 1369\u20131375 (2002).","journal-title":"Nature Med."},{"key":"BFnrc1359_CR147","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/36978","volume":"390","author":"RS Kerbel","year":"1997","unstructured":"Kerbel, R. S. A cancer therapy resistant to resistance. Nature 390, 335\u2013336 (1997).","journal-title":"Nature"},{"key":"BFnrc1359_CR148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(00)79001-4","volume":"79","author":"JM Cherrington","year":"2000","unstructured":"Cherrington, J. M., Strawn, L. M. & Shawver, L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 79, 1\u201338 (2000).","journal-title":"Adv. Cancer Res."},{"key":"BFnrc1359_CR149","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.2000.18.5.1135","volume":"18","author":"AR Nelson","year":"2000","unstructured":"Nelson, A. R., Fingleton, B., Rothenberg, M. L. & Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18, 1135\u20131149 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1359_CR150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1013172910858","volume":"20","author":"RS Kerbel","year":"2001","unstructured":"Kerbel, R. S. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20, 79\u201386 (2001).","journal-title":"Cancer Metastasis Rev."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc1359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1359","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:27:45Z","timestamp":1684456065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":150,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["BFnrc1359"],"URL":"https:\/\/doi.org\/10.1038\/nrc1359","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}